Avacta Group Plc (AVCTF)
USD 0.59
(0.0%)
USD 0.59
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -26.71 Million GBP | 18.16% |
| 2022 | -32.64 Million GBP | -12.25% |
| 2021 | -29.08 Million GBP | -36.58% |
| 2020 | -21.29 Million GBP | -90.41% |
| 2019 | -11.18 Million GBP | -7.21% |
| 2018 | -10.43 Million GBP | -30.7% |
| 2017 | -7.98 Million GBP | -40.91% |
| 2016 | -5.66 Million GBP | -1.74% |
| 2015 | -5.56 Million GBP | -169.33% |
| 2014 | -2.06 Million GBP | -10.36% |
| 2013 | -1.87 Million GBP | -214.07% |
| 2012 | 1.64 Million GBP | 45.96% |
| 2011 | 1.12 Million GBP | -44.47% |
| 2010 | 2.02 Million GBP | -29.09% |
| 2009 | 2.85 Million GBP | 72.9% |
| 2008 | 1.65 Million GBP | 245.71% |
| 2007 | -1.13 Million GBP | -952.63% |
| 2006 | 133 Thousand GBP | -47.22% |
| 2005 | 252 Thousand GBP | -26.53% |
| 2004 | 343 Thousand GBP | 443.0% |
| 2003 | -100 Thousand GBP | -162.5% |
| 2002 | 160 Thousand GBP | 7.38% |
| 2001 | 149 Thousand GBP | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -5.58 Million GBP | 66.21% |
| 2023 Q2 | -11.17 Million GBP | -100.0% |
| 2023 FY | -26.71 Million GBP | 18.16% |
| 2023 Q4 | -15.54 Million GBP | -100.0% |
| 2023 Q3 | -7.77 Million GBP | 30.44% |
| 2022 Q2 | -8.99 Million GBP | -100.0% |
| 2022 Q3 | -8.26 Million GBP | 8.13% |
| 2022 FY | -32.64 Million GBP | -12.25% |
| 2022 Q1 | -4.49 Million GBP | 74.64% |
| 2022 Q4 | -16.53 Million GBP | -100.0% |
| 2021 Q3 | -8.87 Million GBP | 21.69% |
| 2021 Q2 | -11.33 Million GBP | -100.19% |
| 2021 Q4 | -17.74 Million GBP | -99.88% |
| 2021 Q1 | -5.66 Million GBP | 49.57% |
| 2021 FY | -29.08 Million GBP | -36.58% |
| 2020 Q4 | -11.23 Million GBP | -100.0% |
| 2020 Q1 | -4.05 Million GBP | 0.0% |
| 2020 Q2 | -8.1 Million GBP | -100.0% |
| 2020 FY | -21.29 Million GBP | -90.41% |
| 2020 Q3 | -5.61 Million GBP | 30.72% |
| 2019 Q2 | -2.65 Million GBP | 0.0% |
| 2019 FY | -11.18 Million GBP | -7.21% |
| 2019 Q1 | -2.65 Million GBP | 54.78% |
| 2018 Q1 | -2.56 Million GBP | -14.87% |
| 2018 FY | -10.43 Million GBP | -30.7% |
| 2018 Q4 | -5.87 Million GBP | 0.0% |
| 2018 Q2 | -4.97 Million GBP | -93.73% |
| 2017 Q2 | -2.04 Million GBP | 0.0% |
| 2017 Q4 | -2.23 Million GBP | 0.0% |
| 2017 FY | -7.98 Million GBP | -40.91% |
| 2017 Q1 | -2.04 Million GBP | -5.11% |
| 2017 Q3 | -2.23 Million GBP | -9.34% |
| 2016 Q2 | -1.81 Million GBP | 0.0% |
| 2016 FY | -5.66 Million GBP | -1.74% |
| 2016 Q3 | -1.94 Million GBP | -7.49% |
| 2016 Q4 | -1.94 Million GBP | 0.0% |
| 2016 Q1 | -1.81 Million GBP | -77.1% |
| 2015 Q4 | -1.02 Million GBP | 0.0% |
| 2015 FY | -5.56 Million GBP | -169.33% |
| 2015 Q3 | -1.02 Million GBP | -30.94% |
| 2015 Q2 | -780.5 Thousand GBP | 0.0% |
| 2015 Q1 | -780.5 Thousand GBP | 2.38% |
| 2014 Q2 | -617 Thousand GBP | 0.0% |
| 2014 Q1 | -617 Thousand GBP | -113.13% |
| 2014 Q4 | -799.5 Thousand GBP | 0.0% |
| 2014 FY | -2.06 Million GBP | -10.36% |
| 2014 Q3 | -799.5 Thousand GBP | -29.58% |
| 2013 FY | -1.87 Million GBP | -214.07% |
| 2013 Q2 | -449.5 Thousand GBP | 0.0% |
| 2013 Q3 | -289.5 Thousand GBP | 35.6% |
| 2013 Q4 | -289.5 Thousand GBP | 0.0% |
| 2013 Q1 | -449.5 Thousand GBP | 7.7% |
| 2012 Q4 | -487 Thousand GBP | 0.0% |
| 2012 FY | 1.64 Million GBP | 45.96% |
| 2012 Q3 | -487 Thousand GBP | 0.0% |
| 2011 FY | 1.12 Million GBP | -44.47% |
| 2010 FY | 2.02 Million GBP | -29.09% |
| 2009 FY | 2.85 Million GBP | 72.9% |
| 2008 FY | 1.65 Million GBP | 245.71% |
| 2007 FY | -1.13 Million GBP | -952.63% |
| 2006 FY | 133 Thousand GBP | -47.22% |
| 2005 FY | 252 Thousand GBP | -26.53% |
| 2004 FY | 343 Thousand GBP | 443.0% |
| 2003 FY | -100 Thousand GBP | -162.5% |
| 2002 FY | 160 Thousand GBP | 7.38% |
| 2001 FY | 149 Thousand GBP | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1805.647% |
| CSL Limited | 3.7 Billion USD | 100.722% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 62.782% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 643.602% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -10108.004% |
| Evofem Biosciences, Inc. | -17.84 Million USD | -49.7% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 132.641% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -1639.333% |
| Mesoblast Limited | -84.14 Million USD | 68.25% |
| Marizyme, Inc. | -34.08 Million USD | 21.62% |
| Genus plc | 6.4 Million USD | 517.453% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 374.233% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -2768.539% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -219.964% |
| ContraFect Corporation | -56.88 Million USD | 53.037% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -486.578% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -38.67 Million USD | 30.913% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -871.231% |
| MultiCell Technologies, Inc. | -722.81 USD | -3696168.729% |
| Accustem Sciences Inc. | -3.74 Million USD | -613.134% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 54.709% |
| EV Biologics, Inc. | -483.06 Thousand USD | -5430.76% |
| Q BioMed Inc. | -3.44 Million USD | -675.391% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 854.718% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -916.814% |
| Biomind Labs Inc. | -1 Million USD | -2546.288% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -301.879% |
| Skye Bioscience, Inc. | -13.67 Million USD | -95.417% |
| SQZ Biotechnologies Company | -75.82 Million USD | 64.765% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -89099.386% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -429.628% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -837.272% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | -68.352% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -6758.074% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | -447.531% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -1244.942% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -1282.431% |
| GB Sciences, Inc. | -1.42 Million USD | -1780.805% |
| Alpha Cognition Inc. | -9.7 Million USD | -175.274% |
| argenx SE | -425.04 Million USD | 93.714% |
| HST Global, Inc. | -140.9 Thousand USD | -18860.733% |
| Halberd Corporation | -75.05 Thousand USD | -35498.934% |
| Enzolytics Inc. | -2.14 Million USD | -1143.345% |
| Resverlogix Corp. | -12.74 Million USD | -109.562% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -743.267% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 51.868% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 51.399% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -2459.1% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -820.879% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -815.14% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -1333.031% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -1591.64% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -684.645% |
| AVAX Technologies, Inc. | 6.69 Million USD | 499.185% |
| ONE Bio Corp. | 13.68 Million USD | 295.278% |
| Zenith Capital Corp. | -8.94 Million USD | -198.748% |
| Genscript Biotech Corporation | -415.79 Million USD | 93.574% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -153260.886% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -988.128% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -15477.559% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -1232.68% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -2275.043% |
| Agentix Corp. | -1.37 Million USD | -1847.65% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -3.04 Million USD | -778.776% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -2614.996% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -2027.15% |
| BioStem Technologies, Inc. | -7.77 Million USD | -243.452% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -14621.327% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1900.628% |
| LadRx Corporation | -3.82 Million USD | -598.735% |
| Cell Source, Inc. | -4.32 Million USD | -517.685% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -6330.409% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -3789.22% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -3789.22% |
| NovAccess Global Inc. | -2.46 Million USD | -983.081% |
| Affymax, Inc. | -15.04 Million USD | -77.569% |
| Itoco Inc. | -919.14 Thousand USD | -2806.739% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -530.354% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -2287.578% |
| CytoDyn Inc. | -18.05 Million USD | -47.951% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -106046.206% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -12039.787% |
| Qrons Inc. | -643.67 Thousand USD | -4050.684% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -4630.992% |
| SYBLEU INC | -149.18 Thousand USD | -17809.237% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -1098.137% |
| Rebus Holdings, Inc. | -664 Thousand USD | -3923.645% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -1370.941% |
| Mobile Lads Corp. | -554.55 Thousand USD | -4717.78% |
| International Stem Cell Corporation | -663 Thousand USD | -3929.713% |
| Bioxytran, Inc. | -3.82 Million USD | -599.371% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -50654.179% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -131252.016% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 26.33% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -1551.236% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -3530.841% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -758.791% |
| Neutra Corp. | -229.48 Thousand USD | -11542.105% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | -52.329% |
| PureTech Health plc | -146.19 Million USD | 81.726% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | -24.316% |
| IXICO plc | -1.43 Million USD | -1759.221% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -181.498% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 78.066% |
| CSL Limited | 3.81 Billion USD | 100.701% |
| Cellectis S.A. | -108.85 Million USD | 75.457% |